Middle East Conflict Disrupts Pharma Supply Chains: Cancer Drugs at Risk
The ongoing conflict in the Middle East is increasingly disrupting global pharmaceutical supply chains. With key air cargo hubs closed and transport routes rerouted, the delivery of life-saving medicines particularly temperature-sensitive cancer drugs is under growing pressure.
Critical air routes severely affected
The war has forced the closure or disruption of major air transit hubs such as Dubai, Abu Dhabi, and Doha key nodes in global pharmaceutical logistics.
These hubs play a crucial role in connecting Europe, Asia, and Africa, particularly for:
- time-sensitive medicines
- temperature-controlled (“cold chain”) pharmaceuticals
- high-value biologics and oncology treatments
As a result, companies are being forced to rapidly reorganize logistics flows.
Cancer drugs particularly vulnerable
Among the most at-risk products are oncology medicines, especially those requiring strict temperature control and rapid delivery.
Key challenges include:
- short shelf life of certain drugs
- strict storage requirements (cold chain)
- limited flexibility for slower transport modes
Experts warn that delays could have direct clinical consequences, including treatment interruptions or disease progression.
Rerouting strategies and logistical strain
Pharmaceutical companies are actively seeking alternative routes to maintain supply. Current strategies include:
- rerouting shipments via Saudi Arabia, Istanbul, or Oman
- increasing reliance on overland transport
- continuous real-time re-routing of shipments
However, these alternatives come with significant limitations:
- longer transit times
- higher fuel and logistics costs
- limited availability of cold-chain infrastructure
Establishing new temperature-controlled logistics corridors “cannot be done overnight,” industry experts emphasize.
Global impact beyond the region
The disruption affects more than just the Gulf region. Over 20% of global air cargo for critical medicines is exposed to instability in Middle Eastern airspace.
In addition, indirect risks are emerging:
- shortages of packaging materials (e.g. vial stoppers, IV bag plastics)
- increased pressure on global logistics networks
- rising transportation costs across healthcare supply chains
These cascading effects highlight the fragility of highly optimized, just-in-time pharmaceutical systems.
Outlook: Short-term resilience, long-term risk
For now, the pharmaceutical industry is managing to maintain supply through emergency measures and prioritization of critical shipments.
However, experts caution:
- some regions could face shortages within 4–6 weeks if disruptions persist
- prolonged conflict may overwhelm current contingency strategies
- rebuilding stable supply routes could take significant time
Read the full article here.
